Kevin Balthaser - Net Worth and Insider Trading
Kevin Balthaser Net Worth
The estimated net worth of Kevin Balthaser is at least $18,089 dollars as of 2024-05-13. Kevin Balthaser is the CFO of Aclaris Therapeutics Inc and owns about 15,461 shares of Aclaris Therapeutics Inc (ACRS) stock worth over $18,089. Details can be seen in Kevin Balthaser's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kevin Balthaser has not made any transactions after 2023-09-06 and currently still holds the listed stock(s).
Transaction Summary of Kevin Balthaser
Kevin Balthaser Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Kevin Balthaser owns 1 companies in total, including Aclaris Therapeutics Inc (ACRS) .
Click here to see the complete history of Kevin Balthaser’s form 4 insider trades.
Insider Ownership Summary of Kevin Balthaser
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ACRS | Aclaris Therapeutics Inc | 2023-09-06 | Chief Financial Officer |
Kevin Balthaser Latest Holdings Summary
Kevin Balthaser currently owns a total of 1 stock. Kevin Balthaser owns 15,461 shares of Aclaris Therapeutics Inc (ACRS) as of September 6, 2023, with a value of $18,089.
Latest Holdings of Kevin Balthaser
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics Inc | 2023-09-06 | 15,461 | 1.17 | 18,089 |
Holding Weightings of Kevin Balthaser
Kevin Balthaser Form 4 Trading Tracker
According to the SEC Form 4 filings, Kevin Balthaser has made a total of 2 transactions in Aclaris Therapeutics Inc (ACRS) over the past 5 years, including 1 buys and 1 sells. The most-recent trade in Aclaris Therapeutics Inc is the acquisition of 9,490 shares on September 6, 2023, which cost Kevin Balthaser around $74,971.
Insider Trading History of Kevin Balthaser
- 1
Kevin Balthaser Trading Performance
GuruFocus tracks the stock performance after each of Kevin Balthaser's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kevin Balthaser is -86.49%. GuruFocus also compares Kevin Balthaser's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kevin Balthaser within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Kevin Balthaser's insider trading performs compared to the benchmark.
Performance of Kevin Balthaser
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -19.74 |  | | | | |
| Relative Return to S&P 500(%) | -16.22 | | | | | |
Kevin Balthaser Ownership Network
Kevin Balthaser Owned Company Details
What does Aclaris Therapeutics Inc do?
Who are the key executives at Aclaris Therapeutics Inc?
Kevin Balthaser is the Chief Financial Officer of Aclaris Therapeutics Inc. Other key executives at Aclaris Therapeutics Inc include Chief Scientific Officer Joseph Monahan , Chief Business Officer James Loerop , and Pres and COO Douglas J. Manion .
Aclaris Therapeutics Inc (ACRS) Insider Trades Summary
Over the past 18 months, Kevin Balthaser made 2 insider transaction in Aclaris Therapeutics Inc (ACRS) with a net purchase of 7,596. Other recent insider transactions involving Aclaris Therapeutics Inc (ACRS) include a net sale of 53,837 shares made by Joseph Monahan , a net sale of 129,240 shares made by Neal Walker , and a net purchase of 12,800 shares made by Douglas J. Manion .
In summary, during the past 3 months, insiders sold 0 shares of Aclaris Therapeutics Inc (ACRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 243,164 shares of Aclaris Therapeutics Inc (ACRS) were sold and 36,995 shares were bought by its insiders, resulting in a net sale of 206,169 shares.
Aclaris Therapeutics Inc (ACRS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Aclaris Therapeutics Inc Insider Transactions
Kevin Balthaser Mailing Address
Above is the net worth, insider trading, and ownership report for Kevin Balthaser. You might contact Kevin Balthaser via mailing address: C/o Aclaris Therapeutics, Inc., 640 Lee Road, Suite 200, Wayne Pa 19087.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
